[Effects of the combined calcitonin and sodium etidronate therapy in Paget's disease of bone].
The therapy of Paget's bone disease is essentially based on the use of calcitonin and diphosphonates: both drugs, if used in large doses for long periods, have shown themselves able to provoke particular side-effects. It was, therefore, decided to study the therapeutic efficacy of combined low-dosage treatment using synthetic salmon calcitonin and sodium-etidronate on a group of patients with Paget's osteodystrophy. A clear evident diminution in plasma alkaline phosphatase, hydroxyprolinuria and whole body retention (WBR) of MDP-Tc99m was observed, demonstrating a reduction of metabolic turnover in the bone. No changes in the bone mass (BMC), evaluated by bone mineral detector, were observed at the end of treatment. With this treatment the plateau effect was shown to be appreciably less than normally occurs when either calcitonin or sodium etidronate are used alone.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D001842:Bone and Bones / Q000032:analysis / Q000378:metabolism; D002116:Calcitonin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000032:analysis; D010001:Osteitis Deformans / Q000188:drug therapy*
D008903:Minerals; D002116:Calcitonin; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D006909:Hydroxyproline
Effetti della terapia combinata con calcitonina e etidronato sodico nella malattia ossea di Paget.